Aytu Biopharma (AYTU) Current Deferred Revenue (2014 - 2020)

Aytu Biopharma (AYTU) has 6 years of Current Deferred Revenue data on file, last reported at $475680.0 in Q4 2020.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $475680.0 in Q4 2020; TTM through Dec 2020 was $475680.0, a N/A change from a year earlier, with the FY2020 full-year figure at $339336.0, changed N/A from the prior year.
• Current Deferred Revenue for Q4 2020 stood at $475680.0, up from $232576.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for AYTU reached as high as $475680.0 in Q4 2020 and fell as low as $1450.0 in Q2 2018.
• Historically, Current Deferred Revenue has averaged $128421.1 across 4 years, with a median of $6673.0 in 2017.
• On a YoY basis, Current Deferred Revenue climbed as much as 78.27% in 2018 and fell as far as 78.27% in 2018.
• Year by year, Current Deferred Revenue stood at $85714.0 in 2016, then tumbled by 94.42% to $4787.0 in 2017, then plunged by 69.71% to $1450.0 in 2018, then soared by 32705.52% to $475680.0 in 2020.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $475680.0 in Q4 2020, $232576.0 in Q3 2020, and $339336.0 in Q2 2020.